Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2255 Results for "
Immunity
" in MedChemExpress (MCE) Product Catalog:
Products (2255)
2255 Results for "Immunity" in MCE Product Catalog:
Cat. No.: HY-D3227
CAS No.: 2677830-11-2
Cat. No.: HY-P11000
Research Areas:
INF7TAT is an amphipathic cell-penetrating peptide that mediates intracellular delivery of CRISPR ribonucleoproteins. INF7TAT achieves endosomal escape via the INF7 fragment and cell binding via the TAT fragment. It enables intracellular delivery into primary human T cells and hematopoietic stem and progenitor cells, facilitating gene knockout and AAV-mediated homology-directed repair. INF7TAT can be used for genome editing-related research .
Cat. No.: HY-P11000A
Research Areas:
INF7TAT acetate is an amphipathic cell-penetrating peptide that mediates intracellular delivery of CRISPR ribonucleoproteins. INF7TAT acetate achieves endosomal escape via the INF7 fragment and cell binding via the TAT fragment. It enables intracellular delivery into primary human T cells and hematopoietic stem and progenitor cells, facilitating gene knockout and AAV-mediated homology-directed repair. INF7TAT acetate can be used for genome editing-related research .
Cat. No.: HY-P991396
Cat. No.: HY-149043
CAS No.: 1451079-18-7
Target:
Research Areas:
NIK-IN-1 (Compound 2) is an inhibitor of NF-κB-inducing kinase (NIK). NIK-IN-1 is used for research on hepatic inflammatory diseases and acute liver injury .
Cat. No.: HY-185565
CAS No.: 2691796-92-4
Target:
Research Areas:
PD-1/PD-L1-IN-63 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 9.1 nM. PD-1/PD-L1-IN-63 blocks the PD-1/PD-L1 interaction, induces cancer cell death and inhibits tumor growth. PD-1/PD-L1-IN-63 can be used in the research of melanoma .
Cat. No.: HY-76476
CAS No.: 86087-23-2
Synonyms: (+)-3-Hydroxytetrahydrofuran
Target:
Research Areas:
(S)-Tetrahydrofuran-3-ol ((+)-3-Hydroxytetrahydrofuran) is a secondary alcohol and the (S)-enantiomer of Tetrahydrofuran-3-ol. (S)-Tetrahydrofuran-3-ol serves as a crucial chiral alcohol intermediate for the human immunodeficiency virus inhibitor Amprenavir (HY-17430). (S)-Tetrahydrofuran-3-ol is applicable to researches on chiral biocatalysis and synthesis of HIV protease inhibitor intermediates .
Cat. No.: HY-76476R
CAS No.: 86087-23-2
Synonyms: (+)-3-Hydroxytetrahydrofuran (Standard)
Research Areas:
(S)-Tetrahydrofuran-3-ol (Standard) ((+)-3-Hydroxytetrahydrofuran (Standard)) is the analytical standard of (S)-Tetrahydrofuran-3-ol (HY-76476). This product is intended for research and analytical applications. (S)-Tetrahydrofuran-3-ol ((+)-3-Hydroxytetrahydrofuran) is a secondary alcohol and the (S)-enantiomer of Tetrahydrofuran-3-ol. (S)-Tetrahydrofuran-3-ol serves as a crucial chiral alcohol intermediate for the human immunodeficiency virus inhibitor Amprenavir (HY-17430). (S)-Tetrahydrofuran-3-ol is applicable to researches on chiral biocatalysis and synthesis of HIV protease inhibitor intermediates .
Cat. No.: HY-N7700
CAS No.: 15769-56-9
Synonyms: G2013
Target:
Research Areas:
Guluronic acid (G2013) is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases .
Cat. No.: HY-P990953
CAS No.: 2640279-10-1
Synonyms: Gen1047
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
Cat. No.: HY-P991745
Cat. No.: HY-112624E
CAS No.: 9004-54-0
Synonyms: Dextran 0.8; Dextran D0.8; Dextran T0.8(MW 640-960)
Cat. No.: HY-112624J
CAS No.: 9004-54-0
Synonyms: Dextran 4; Dextran D4; Dextran T4(MW 3200-4800)
Target:
Research Areas:
DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
Cat. No.: HY-114243A
CAS No.: 1382469-40-0
Target:
Research Areas:
Neurological Disease Inflammation/Immunology Endocrinology Cancer
DpC hydrochloride is a selective, orally active iron chelator with anticancer activity. DpC hydrochloride acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC hydrochloride induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC hydrochloride inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC hydrochloride is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
Cat. No.: HY-119715
CAS No.: 486414-35-1
Research Areas:
AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
Cat. No.: HY-125101A
CAS No.: 1257792-42-9
Rafutrombopag (Hetrombopag) diolamine is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag diolamine can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag diolamine specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag diolamine effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag diolamine protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag diolamine can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
Cat. No.: HY-126855S
CAS No.: 1332881-66-9
Synonyms: 7-Sulfocholic acid-d4
Cat. No.: HY-14519AR
CAS No.: 7413-34-5
Synonyms: Amethopterin disodium (Standard); CL14377 disodium (Standard); WR19039 disodium (Standard)
Methotrexate disodium (Standard) (Amethopterin disodium (Standard); CL14377 disodium (Standard); WR19039 disodium (Standard)) is the analytical standard of Methotrexate disodium (HY-14519A). This product is intended for research and analytical applications. Methotrexate disodium (Amethopterin disodium; CL14377 disodium; WR19039 disodium) is an orally active antifolate (Antifolate). Methotrexate disodium inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate disodium promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate disodium induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate disodium is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer .
Cat. No.: HY-148511
CAS No.: 147063-80-7
Synonyms: CMP-001
Research Areas:
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
